These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 17060271

  • 1. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
    Massacesi C, Galeazzi G.
    Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
    [Abstract] [Full Text] [Related]

  • 2. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
    Shima Y, Ohtsu A, Shirao K, Sasaki Y.
    Jpn J Clin Oncol; 2008 May; 38(5):354-9. PubMed ID: 18490369
    [Abstract] [Full Text] [Related]

  • 3. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
    Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, Kizawa Y, Maeno T, Shima Y, Hyodo I.
    Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Octreotide for malignant bowel obstruction: twenty years after.
    Mercadante S, Porzio G.
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction.
    Zhang Y, Gao Y, Ma Q, Dang C, Wei W, De Antoni F, Rocci R, Chen W.
    Dig Liver Dis; 2006 Mar; 38(3):188-94. PubMed ID: 16311083
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
    Penning C, Vecht J, Masclee AA.
    Aliment Pharmacol Ther; 2005 Nov 15; 22(10):963-9. PubMed ID: 16268971
    [Abstract] [Full Text] [Related]

  • 13. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
    Nikou GC, Toumpanakis C, Katsiari C, Charalambopoulos D, Sfikakis PP.
    J Clin Rheumatol; 2007 Jun 15; 13(3):119-23. PubMed ID: 17551375
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Effective made of octreotide intravenous administration for malignant gastrointestinal obstruction in terminal cancer patients].
    Tanimura K, Onda S, Mitsunobu M.
    Gan To Kagaku Ryoho; 2010 Oct 15; 37(10):1991-3. PubMed ID: 20948271
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.